Bullet Biotechnology Inc MENU WELCOME TO ONCTERNAL THERAPEUTICS With a pipeline that includes two clinical-stage products, we’re committed to translate pioneering areas of cancer research into approved therapies that can be used to treat multiple cancer types. We are working quickly to advance our clinical programs, leveraging our team’s strong experience and a network of academic collaborations. ABOUT OUR SCIENCE MEET OUR TEAM LATEST NEWS JUN 01 2016 Oncternal Merges with Tokalas to Form Clinical-Stage Biotech Company w/ Promising Oncology Pipeline APR 12 2016 Oncternal Awarded Exclusive Worldwide License to ROR1 Antibody and Related Programs from UCSD Clinical-Stage Products FOR RARE CANCERS Cirmtuzumab HUMANIZED MONOCLONAL ANTIBODY TK216 TRANSCRIPTION FACTOR INHIBITOR We are recruiting patients with CLL for a Phase 1 study of Cirmtuzumab, our anti-ROR1 monoclonal antibody. PARTICIPATE IN OUR TRIAL Send Me News Updates by Email BACK TO HOME Contact © 2016 Oncternal Therapeutics. All rights reserved. Website by Centrifuge Media Lab.

Bullet Biotechnology Inc MENU MEET OUR TEAM Management James Breitmeyer, MD, PhD President & Chief Executive Officer James Freddo, MD Chief Medical Officer Lauren Otsuki Chief Business Officer Brian Lannutti, PhD Chief Scientific Officer Dana McGowan Chief Financial Officer Board of Directors Dave Johnson Chairman David Hale Director Scott Glenn Director Cam Garner Director James Breitmeyer, MD, PhD President & Chief Executive Officer Scientific Advisors Jeffrey Toretsky, MD Thomas Kipps, MD, PhD Send Me News Updates by Email BACK TO HOME Contact © 2016 Oncternal Therapeutics. All rights reserved. Website by Centrifuge Media Lab.

Bullet Biotechnology Inc MENU FOR PATIENTS Clinical Trials for Unmet Needs With an eternal focus on oncology, we are committed to advancing our pipeline and bringing patients a new wave of therapies. Our product pipeline is focused on novel targets that are uniquely expressed within cancer cells, enabling therapies that are highly targeted with potential to treat both rare and common cancers. With our pipeline of two clinical-stage compounds, we are supporting and/or planning several clinical studies to help address patient needs: Cirmtuzumab UC-961 (cirmtuzumab) in relapsed or refractory chronic lymphocytic leukemia Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer TK216 TK216 in Patients with Relapsed or Refractory Ewing Sarcoma Send Me News Updates by Email BACK TO HOME Contact © 2016 Oncternal Therapeutics. All rights reserved. Website by Centrifuge Media Lab.